Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 7.5 USD -1.45%
Market Cap: 512.9m USD
Have any thoughts about
Phathom Pharmaceuticals Inc?
Write Note

Phathom Pharmaceuticals Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Phathom Pharmaceuticals Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Current Portion of Long-Term Debt
$7.1m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Current Portion of Long-Term Debt
$2.5B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Current Portion of Long-Term Debt
$873m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Current Portion of Long-Term Debt
$3.7B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Current Portion of Long-Term Debt
$3.1B
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
-10%
Eli Lilly and Co
NYSE:LLY
Current Portion of Long-Term Debt
$2.1B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
21%
No Stocks Found

Phathom Pharmaceuticals Inc
Glance View

Market Cap
512.4m USD
Industry
Pharmaceuticals

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

PHAT Intrinsic Value
9.34 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Phathom Pharmaceuticals Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
7.1m USD

Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Current Portion of Long-Term Debt amounts to 7.1m USD.

What is Phathom Pharmaceuticals Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-1%

The average annual Current Portion of Long-Term Debt growth rates for Phathom Pharmaceuticals Inc have been -1% over the past three years .

Back to Top